Cargando…

Persistence, Adherence, and Switching to Higher-Cost Therapy in Patients with Multiple Sclerosis Initiating Oral Disease-Modifying Therapies: A Retrospective Real-World Study

INTRODUCTION: Therapeutic efficacy of disease-modifying therapies (DMTs) for multiple sclerosis (MS) is often hindered by poor persistence and adherence, impacted by patient-perceived efficacy concerns, adverse effects, inconvenience, and forgetfulness. This study measured persistence, adherence, an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Araujo, Lita, Geertsen, Svend S., Amedume, Allen, Higuchi, Keiko, van Wingerden, Janneke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588137/ https://www.ncbi.nlm.nih.gov/pubmed/36152222 http://dx.doi.org/10.1007/s40120-022-00404-1

Ejemplares similares

Health economic outcomes of switching to alemtuzumab from other disease-modifying therapies in people with multiple sclerosis in the USA
por: Araujo, Lita, et al.
Publicado: (2022)

Assessing the Health Economic Outcomes from Commercially Insured Relapsing Multiple Sclerosis Patients Who Switched from Other Disease-Modifying Therapies to Teriflunomide, in the United States
por: Araujo, Lita, et al.
Publicado: (2023)

Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry
por: Papp, Viktoria, et al.
Publicado: (2021)

Real-world Evidence for Adherence and Persistence with Atorvastatin Therapy
por: Tsioufis, Konstantinos, et al.
Publicado: (2021)

Predictors of adherence and persistence to disease-modifying therapies in Multiple Sclerosis
por: Zanga, Gisela, et al.
Publicado: (2021)

The Association Between Persistence and Adherence to Disease-Modifying Therapies and Healthcare Resource Utilization and Costs in Patients With Multiple Sclerosis
por: Pardo, Gabriel, et al.
Publicado: (2022)

Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide
por: Tornatore, Carlo, et al.
Publicado: (2022)

Adherence and Persistence to Medical Therapy in Glaucoma: An Overview
por: Quaranta, Luciano, et al.
Publicado: (2023)

Adherence to Therapy in Patients with Multiple Sclerosis—Review
por: Kołtuniuk, Aleksandra, et al.
Publicado: (2022)

Adherence to Disease-Modifying Therapies for Multiple Sclerosis
por: Higuera, Lucas, et al.
Publicado: (2016)

Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis
por: Lager, Brittney, et al.
Publicado: (2022)

Adherence to and Persistence with Disease-Modifying Therapies for Multiple Sclerosis Over 24 Months: A Retrospective Claims Analysis
por: Pardo, Gabriel, et al.
Publicado: (2022)

Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data
por: Engmann, Natalie J, et al.
Publicado: (2021)

Medication Adherence and Healthcare Utilization in Relapsing-Remitting Multiple Sclerosis Patients Using Teriflunomide
por: Greene, Nupur, et al.
Publicado: (2022)

Persistence and adherence to biologic therapies in juvenile idiopathic arthritis
por: Nieto-González, Juan Carlos, et al.
Publicado: (2021)

Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real‐world claims data analysis
por: Sussman, D., et al.
Publicado: (2017)

Real‐world evaluation of the impact of statin intensity on adherence and persistence to therapy: A Scottish population‐based study
por: Rezende Macedo do Nascimento, Renata Cristina, et al.
Publicado: (2020)

Multiple Sclerosis Patients Treated With Diroximel Fumarate in the Real-World Setting Have High Rates of Persistence and Adherence
por: Liseno, Jacob, et al.
Publicado: (2021)

Effect of Cost and Formulation on Persistence and Adherence to Initial Metformin Therapy for Type 2 Diabetes
por: Flory, James H., et al.
Publicado: (2020)

The Impact of Comorbid Depression on Adherence to Therapy for Multiple Sclerosis
por: Tarrants, M., et al.
Publicado: (2011)

Adherence to disease-modifying therapies in patients with multiple sclerosis
por: Kołtuniuk, Aleksandra, et al.
Publicado: (2018)

Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis
por: Halpern, Rachel, et al.
Publicado: (2011)

Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence
por: Patti, Francesco
Publicado: (2010)

Adherence, Persistence, Readmissions, and Costs in Medicaid Members with Schizophrenia or Schizoaffective Disorder Initiating Paliperidone Palmitate Versus Switching Oral Antipsychotics: A Real-World Retrospective Investigation
por: Dickson, Matthew C., et al.
Publicado: (2022)

Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy
por: Moccia, Marcello, et al.
Publicado: (2022)

Letter to the Editor Regarding: “Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis”
por: Nieto-Gómez, Pelayo, et al.
Publicado: (2023)

Switching Multiple Sclerosis Patients with Breakthrough Disease to Second-Line Therapy
por: Castillo-Trivino, Tamara, et al.
Publicado: (2011)

Switching and Escalating Therapy in Long-Lasting Multiple Sclerosis: Not Always Necessary
por: Carvalho, Ana Teresa, et al.
Publicado: (2012)

Adherence to and Persistence with Adalimumab Therapy among Swedish Patients with Crohn’s Disease
por: Liu, Yifei, et al.
Publicado: (2022)

Medication adherence/persistence among patients with active multiple sclerosis in Finland
por: Lahdenperä, Sanni, et al.
Publicado: (2020)

Impaired Ability to Suppress Excitability of Antagonist Motoneurons at Onset of Dorsiflexion in Adults with Cerebral Palsy
por: Geertsen, Svend Sparre, et al.
Publicado: (2018)

Real-world adherence to topical therapies in patients with moderate acne
por: Lam Hoai, Xuân-Lan, et al.
Publicado: (2021)

Psychosocial predictors of patient adherence to disease-modifying therapies for multiple sclerosis
por: Alosaimi, Fahad D, et al.
Publicado: (2017)

Adherence to Therapy, Physical and Mental Quality of Life in Patients with Multiple Sclerosis
por: Buja, Alessandra, et al.
Publicado: (2021)

Response to Letter to the Editor Regarding “Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis”
por: Lager, Brittney, et al.
Publicado: (2023)

Real-world impact of reminder packaging on antihypertensive treatment adherence and persistence
por: Dupclay, Leon, et al.
Publicado: (2012)

Oscillatory Corticospinal Activity during Static Contraction of Ankle Muscles Is Reduced in Healthy Old versus Young Adults
por: Spedden, Meaghan Elizabeth, et al.
Publicado: (2018)

Persistence to disease-modifying therapies for multiple sclerosis in a Canadian cohort
por: Melesse, Dessalegn Y, et al.
Publicado: (2017)

Weight Change and the Association with Adherence and Persistence to Diabetes Therapy: A Narrative Review
por: Boye, Kristina S, et al.
Publicado: (2022)

Prevalence and Determinants of Adherence to Oral Adjuvant Endocrine Therapy among Breast Cancer Patients in Singapore
por: Ali, Eskinder Eshetu, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_m2kt9fdchog7h2pqusbae87f6g